Skip to main content
Top
Published in: Cardiovascular Ultrasound 1/2015

Open Access 01-12-2015 | Research

Long-term clinical and echocardiographic outcomes of extensive septal myectomy for hypertrophic obstructive cardiomyopathy in Chinese patients

Authors: Lei Yao, Li Li, Xiong-Jun Lu, Yan-Ling Miao, Xiao-Ning Kang, Fu-Jian Duan

Published in: Cardiovascular Ultrasound | Issue 1/2015

Login to get access

Abstract

Background

There has been limited data addressing outcomes of extensive septal myectomy in Chinese patients with hypertrophic obstructive cardiomyopathy (HOCM). In this study, the objective was to evaluate the clinical and echocardiographic outcomes of extensive septal myectomy in a relative large number of Chinese HOCM patients over long-term follow-up.

Methods

We retrospectively studied 139 consecutive HOCM patients (age 43 ± 15 years, 37 % male) who underwent extensive left ventricular septal myectomy. During the perioperative period, all patients were examined by echocardiography. All-cause death and cardiac death were considered as primary endpoints during follow-up. Perioperative data was obtained by retrospective review of institutional surgical databases. Follow-up data of echocardiography and clinical status was recorded through outpatient interview.

Results

Perioperative events consisted of arrhythmia, retraction injury to aortic valve leaflets, pleural effusion, and hemodialysis and the use of intra-aortic balloon pump. There was no in-hospital mortality. The follow-up period averaged 5.6 ± 0.9 years and overall survivals were 100.0, 99.3, 99.3, 98.5 and 97.8 % at 1, 2, 3, 4 and 5 years, respectively. Left ventricular outflow tract (LVOT) gradient decreased form preoperative 84 ± 17 mmHg to 12 ± 3 mmHg at 2.5 years after surgery and it further reduced to 6 ± 3 mmHg at 5 years after surgery (P < 0.05). Compared with the preoperative levels, interventricualr septal thickness decreased by 32 % while diastole left ventricular inner diameter approximately increased by 10 % and ejection fraction (EF) was significantly elevated during follow-up (P < 0.05). By echocardiography detection, mitral regurgitation was ameliorated for HOCM patients after surgery. There was significant improvement in New York Heart Association (NYHA) class. The proportion of NYHA III and IV decreased from preoperative 58 to 19 % at 2.5 years after surgery and it reduced to 11 % at 5 years after operation.

Conclusion

Extensive septal myectomy offers minimal operative risk and provides long-term relief for LVOT obstruction in Chinese HOCM patients.
Literature
2.
go back to reference Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249–54.CrossRefPubMed Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249–54.CrossRefPubMed
3.
go back to reference Lopes LR, Syrris P, Guttmann OP, O’Mahony C, Tang HC, Dalageorgou C, et al. Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. Heart. 2015;101:294–301.CrossRefPubMed Lopes LR, Syrris P, Guttmann OP, O’Mahony C, Tang HC, Dalageorgou C, et al. Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. Heart. 2015;101:294–301.CrossRefPubMed
4.
go back to reference Roma-Rodrigues C, Fernandes AR. Genetics of hypertrophic cardiomyopathy: advances and pitfalls in molecular diagnosis and therapy. Appl Clin Genet. 2014;7:195–208.PubMedPubMedCentral Roma-Rodrigues C, Fernandes AR. Genetics of hypertrophic cardiomyopathy: advances and pitfalls in molecular diagnosis and therapy. Appl Clin Genet. 2014;7:195–208.PubMedPubMedCentral
5.
go back to reference Loar RW, Bos JM, Will ML, Ommen SR, Ackerman MJ. Genotype-phenotype Correlations of Hypertrophic Cardiomyopathy When Diagnosed in Children, Adolescents, and Young Adults. Congenit Heart Dis. 2015;10(6):529–36.CrossRefPubMed Loar RW, Bos JM, Will ML, Ommen SR, Ackerman MJ. Genotype-phenotype Correlations of Hypertrophic Cardiomyopathy When Diagnosed in Children, Adolescents, and Young Adults. Congenit Heart Dis. 2015;10(6):529–36.CrossRefPubMed
6.
go back to reference Brown ML, Schaff HV. Surgical management of obstructive hypertrophic cardiomyopathy: the gold standard. Expert Rev Cardiovasc Ther. 2008;6:715–22.CrossRefPubMed Brown ML, Schaff HV. Surgical management of obstructive hypertrophic cardiomyopathy: the gold standard. Expert Rev Cardiovasc Ther. 2008;6:715–22.CrossRefPubMed
7.
go back to reference Liebregts M, Vriesendorp PA, Mahmoodi BK, Schinkel AF, Michels M, ten Berg JM. A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction Therapy in Patients With Hypertrophic Cardiomyopathy. JACC Heart Fail. 2015;3:896–905.CrossRefPubMed Liebregts M, Vriesendorp PA, Mahmoodi BK, Schinkel AF, Michels M, ten Berg JM. A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction Therapy in Patients With Hypertrophic Cardiomyopathy. JACC Heart Fail. 2015;3:896–905.CrossRefPubMed
8.
go back to reference Leonardi RA, Kransdorf EP, Simel DL, Wang A. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv. 2010;3:97–104.CrossRefPubMed Leonardi RA, Kransdorf EP, Simel DL, Wang A. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv. 2010;3:97–104.CrossRefPubMed
9.
go back to reference Said SM, Dearani JA, Ommen SR, Schaff HV. Surgical treatment of hypertrophic cardiomyopathy. Expert Rev Cardiovasc Ther. 2013;11:617–27.CrossRefPubMed Said SM, Dearani JA, Ommen SR, Schaff HV. Surgical treatment of hypertrophic cardiomyopathy. Expert Rev Cardiovasc Ther. 2013;11:617–27.CrossRefPubMed
10.
go back to reference Minakata K, Dearani JA, Nishimura RA, Maron BJ, Danielson GK. Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae. J Thorac Cardiovasc Surg. 2004;127:481–9.CrossRefPubMed Minakata K, Dearani JA, Nishimura RA, Maron BJ, Danielson GK. Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae. J Thorac Cardiovasc Surg. 2004;127:481–9.CrossRefPubMed
11.
go back to reference Schaff HV, Dearani JA, Ommen SR, Sorajja P, Nishimura RA. Expanding the indications for septal myectomy in patients with hypertrophic cardiomyopathy: results of operation in patients with latent obstruction. J Thorac Cardiovasc Surg. 2012;143:303–9.CrossRefPubMed Schaff HV, Dearani JA, Ommen SR, Sorajja P, Nishimura RA. Expanding the indications for septal myectomy in patients with hypertrophic cardiomyopathy: results of operation in patients with latent obstruction. J Thorac Cardiovasc Surg. 2012;143:303–9.CrossRefPubMed
12.
go back to reference Williams LK, Rakowski H. Surgical myectomy for hypertrophic obstructive cardiomyopathy: the cut that heals. Circulation. 2013;128:193–7.CrossRefPubMed Williams LK, Rakowski H. Surgical myectomy for hypertrophic obstructive cardiomyopathy: the cut that heals. Circulation. 2013;128:193–7.CrossRefPubMed
13.
go back to reference Ashikhmina EA, Schaff HV, Ommen SR, Dearani JA, Nishimura RA, Abel MD. Intraoperative direct measurement of left ventricular outflow tract gradients to guide surgical myectomy for hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2011;142:53–9.CrossRefPubMed Ashikhmina EA, Schaff HV, Ommen SR, Dearani JA, Nishimura RA, Abel MD. Intraoperative direct measurement of left ventricular outflow tract gradients to guide surgical myectomy for hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2011;142:53–9.CrossRefPubMed
14.
go back to reference Dearani JA, Ommen SR, Gersh BJ, Schaff HV, Danielson GK. Surgery insight: Septal myectomy for obstructive hypertrophic cardiomyopathy--the Mayo Clinic experience. Nat Clin Pract Cardiovasc Med. 2007;4:503–12.CrossRefPubMed Dearani JA, Ommen SR, Gersh BJ, Schaff HV, Danielson GK. Surgery insight: Septal myectomy for obstructive hypertrophic cardiomyopathy--the Mayo Clinic experience. Nat Clin Pract Cardiovasc Med. 2007;4:503–12.CrossRefPubMed
15.
go back to reference Balaram SK, Ross RE, Sherrid MV, Schwartz GS, Hillel Z, Winson G, et al. Role of mitral valve plication in the surgical management of hypertrophic cardiomyopathy. Ann Thorac Surg. 2012;94:1990–7.CrossRefPubMed Balaram SK, Ross RE, Sherrid MV, Schwartz GS, Hillel Z, Winson G, et al. Role of mitral valve plication in the surgical management of hypertrophic cardiomyopathy. Ann Thorac Surg. 2012;94:1990–7.CrossRefPubMed
16.
go back to reference Melacini P, Basso C, Angelini A, Calore C, Bobbo F, Tokajuk B, et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J. 2010;31:2111–23.CrossRefPubMedPubMedCentral Melacini P, Basso C, Angelini A, Calore C, Bobbo F, Tokajuk B, et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J. 2010;31:2111–23.CrossRefPubMedPubMedCentral
17.
go back to reference Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:2761–96.CrossRefPubMed Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:2761–96.CrossRefPubMed
18.
go back to reference Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114:2232–9.CrossRefPubMed Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114:2232–9.CrossRefPubMed
19.
go back to reference Hamada M, Ikeda S, Shigematsu Y. Advances in medical treatment of hypertrophic cardiomyopathy. J Cardiol. 2014;64:1–10.CrossRefPubMed Hamada M, Ikeda S, Shigematsu Y. Advances in medical treatment of hypertrophic cardiomyopathy. J Cardiol. 2014;64:1–10.CrossRefPubMed
20.
go back to reference Musat D, Sherrid MV. Pathophysiology of hypertrophic cardiomyopathy determines its medical treatment. Anadolu Kardiyol Derg. 2006;6 Suppl 2:9–17.PubMed Musat D, Sherrid MV. Pathophysiology of hypertrophic cardiomyopathy determines its medical treatment. Anadolu Kardiyol Derg. 2006;6 Suppl 2:9–17.PubMed
21.
go back to reference Maron MS. My approach to clinical management of hypertrophic cardiomyopathy. Trends Cardiovasc Med. 2014;24:314–5.CrossRefPubMed Maron MS. My approach to clinical management of hypertrophic cardiomyopathy. Trends Cardiovasc Med. 2014;24:314–5.CrossRefPubMed
22.
go back to reference Cleland WP. The Surgical Management of Obstructive Cardiomyopathy. J Cardiovasc Surg. 1963;4:489–91. Cleland WP. The Surgical Management of Obstructive Cardiomyopathy. J Cardiovasc Surg. 1963;4:489–91.
23.
go back to reference Marwick TH, Stewart WJ, Lever HM, Lytle BW, Rosenkranz ER, Duffy CI, et al. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. J Am Coll Cardiol. 1992;20:1066–72.CrossRefPubMed Marwick TH, Stewart WJ, Lever HM, Lytle BW, Rosenkranz ER, Duffy CI, et al. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. J Am Coll Cardiol. 1992;20:1066–72.CrossRefPubMed
24.
go back to reference Cho YH, Quintana E, Schaff HV, Nishimura RA, Dearani JA, Abel MD, et al. Residual and recurrent gradients after septal myectomy for hypertrophic cardiomyopathy-mechanisms of obstruction and outcomes of reoperation. J Thorac Cardiovasc Surg. 2014;148:909–15.CrossRefPubMed Cho YH, Quintana E, Schaff HV, Nishimura RA, Dearani JA, Abel MD, et al. Residual and recurrent gradients after septal myectomy for hypertrophic cardiomyopathy-mechanisms of obstruction and outcomes of reoperation. J Thorac Cardiovasc Surg. 2014;148:909–15.CrossRefPubMed
25.
go back to reference Dearani JA, Danielson GK. Septal myectomy for obstructive hypertrophic cardiomyopathy. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2005:86-91. Dearani JA, Danielson GK. Septal myectomy for obstructive hypertrophic cardiomyopathy. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2005:86-91.
26.
go back to reference Knyshov G, Lazoryshynets V, Rudenko K, Kravchuk B, Beshlyaga V, Zalevsky V, et al. Is surgery the gold standard in the treatment of obstructive hypertrophic cardiomyopathy? Interact Cardiovasc Thorac Surg. 2013;16:5–9.CrossRefPubMed Knyshov G, Lazoryshynets V, Rudenko K, Kravchuk B, Beshlyaga V, Zalevsky V, et al. Is surgery the gold standard in the treatment of obstructive hypertrophic cardiomyopathy? Interact Cardiovasc Thorac Surg. 2013;16:5–9.CrossRefPubMed
27.
go back to reference Wang S, Luo M, Sun H, Song Y, Yin C, Wang L, et al. A retrospective clinical study of transaortic extended septal myectomy for obstructive hypertrophic cardiomyopathy in China. Eur J Cardiothorac Surg. 2013;43:534–40.CrossRefPubMed Wang S, Luo M, Sun H, Song Y, Yin C, Wang L, et al. A retrospective clinical study of transaortic extended septal myectomy for obstructive hypertrophic cardiomyopathy in China. Eur J Cardiothorac Surg. 2013;43:534–40.CrossRefPubMed
28.
go back to reference Vriesendorp PA, Schinkel AF, Soliman OI, Kofflard MJ, de Jong PL, van Herwerden LA, et al. Long-term benefit of myectomy and anterior mitral leaflet extension in obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2015;115:670–5.CrossRefPubMed Vriesendorp PA, Schinkel AF, Soliman OI, Kofflard MJ, de Jong PL, van Herwerden LA, et al. Long-term benefit of myectomy and anterior mitral leaflet extension in obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2015;115:670–5.CrossRefPubMed
29.
go back to reference Steggerda RC, Damman K, Balt JC, Liebregts M, ten Berg JM, van den Berg MP. Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience. J Am Coll Cardiol Intv. 2014;7:1227–34.CrossRef Steggerda RC, Damman K, Balt JC, Liebregts M, ten Berg JM, van den Berg MP. Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience. J Am Coll Cardiol Intv. 2014;7:1227–34.CrossRef
30.
go back to reference Parry DJ, Raskin RE, Poynter JA, Ribero IB, Bajona P, Rakowski H, et al. Short and medium term outcomes of surgery for patients with hypertrophic obstructive cardiomyopathy. Ann Thorac Surg. 2015;99:1213–9.CrossRefPubMed Parry DJ, Raskin RE, Poynter JA, Ribero IB, Bajona P, Rakowski H, et al. Short and medium term outcomes of surgery for patients with hypertrophic obstructive cardiomyopathy. Ann Thorac Surg. 2015;99:1213–9.CrossRefPubMed
Metadata
Title
Long-term clinical and echocardiographic outcomes of extensive septal myectomy for hypertrophic obstructive cardiomyopathy in Chinese patients
Authors
Lei Yao
Li Li
Xiong-Jun Lu
Yan-Ling Miao
Xiao-Ning Kang
Fu-Jian Duan
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Cardiovascular Ultrasound / Issue 1/2015
Electronic ISSN: 1476-7120
DOI
https://doi.org/10.1186/s12947-016-0060-9

Other articles of this Issue 1/2015

Cardiovascular Ultrasound 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.